Reinduction of relapsed acute promyelocytic leukemia with ATRA and low dose antimetabolite-based chemotherapy.

Pediatr Blood Cancer

Division of Pediatric Hematology, Oncology, and Bone Marrow Transplantation, Stanford University School of Medicine, Palo Alto, California 94304, USA.

Published: May 2007

While the disease-free survival of acute promyelocytic leukemia (APML) now approaches 75%, some children continue to experience relapses, and questions remain as to the optimal management of these patients. We describe two young children who experienced combined relapses in the bone marrow and extramedullary locations following hematopoietic stem cell transplantation (HSCT). An induction regimen, consisting of all-trans retinoic acid (ATRA), methotrexate, and 6-mercaptopurine (6MP), successfully and safely achieved hematologic remission in one patient and molecular remission in the other. These cases demonstrate that there is a role for ATRA plus differentiating chemotherapy other than arsenic trioxide in the treatment of relapsed APML.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.20592DOI Listing

Publication Analysis

Top Keywords

acute promyelocytic
8
promyelocytic leukemia
8
reinduction relapsed
4
relapsed acute
4
leukemia atra
4
atra low
4
low dose
4
dose antimetabolite-based
4
antimetabolite-based chemotherapy
4
chemotherapy disease-free
4

Similar Publications

The biological and thermal properties of a class of synthetic dihydroimidazotriazinones were disclosed in this article for the first time. Molecules --as potential innovative antimetabolites mimicking bicyclic aza-analogues of isocytosine-were evaluated for their in vitro anticancer activity. Moreover, in vivo, in vitro, and ex vivo toxicity profiles of all the compounds were established in zebrafish, non-tumour cell, and erythrocyte models, respectively.

View Article and Find Full Text PDF

An obstacle for many microfluidic developments is the fabrication of its structures, which is often complex, time-consuming, and expensive. Additive manufacturing can help to reduce these barriers. This study investigated whether the results of a microfluidic assay for the detection of the promyelocytic leukemia (PML)-retinoic acid receptor α (RARα) fusion protein (PML::RARA), and thus for the differential diagnosis of acute promyelocytic leukemia (APL), could be transferred from borosilicate glass microfluidic structures to additively manufactured fluidics.

View Article and Find Full Text PDF

Background: Acute promyelocytic leukemia (APL) is characterized by abnormal promyelocytes and t(15;17)(q24;q21) . Rarely, patients may have cryptic or variant rearrangements. All-trans retinoic acid (ATRA)/arsenic trioxide (ATO) is largely curative provided that the diagnosis is established early.

View Article and Find Full Text PDF

Unlabelled: Acute myeloid leukemia (AML) is the most frequent type of leukemia in adults and has a high mortality burden. Patients over 60 years of age infrequently receive high-intensity chemotherapy.

Aim: To describe the clinical characteristics and evaluate the survival in patients with AML, focusing on patients over 60 years.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!